TEL AVIV, Israel, Aug. 5, 2026
SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. has initiated a Phase IIb clinical trial site for SCI-110 at the Yale Child Study Center, Yale School of Medicine, marking a significant expansion of its global clinical development program for Tourette Syndrome (TS). The study, led by Dr. Michael H. Bloch, will evaluate SCI-110, NeuroThera’s proprietary cannabinoid-based drug candidate, in adults with Tourette Syndrome. The investigational therapy combines dronabinol with palmitoylethanolamide (PEA) in a single oral formulation designed to reduce motor and vocal tics while minimizing treatment-related side effects. The Yale site joins ongoing trial locations at Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel, further strengthening the multinational Phase IIb program.
Phase IIb Study Builds on Positive Early Clinical Results
The Phase IIb clinical trial is a randomized, double-blind, placebo-controlled, cross-over study designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110 in adults aged 18 to 65 years diagnosed with Tourette Syndrome. Participants will receive either SCI-110 or placebo, with treatment effects assessed using the Yale Global Tic Severity Scale (YGTSS), the gold-standard measurement for tic severity. The primary endpoint will evaluate changes in tic severity at Weeks 12 and 26 compared with baseline, while safety assessments will include continuous monitoring of adverse events. The study follows encouraging Phase IIa data, where SCI-110 demonstrated an average 21% reduction in tic severity, supporting continued clinical development of the therapy.
SCI-110 Targets Significant Unmet Need in Tourette Syndrome
Tourette Syndrome remains a chronic neurological disorder with limited treatment options, particularly for adults who continue to experience severe motor and vocal tics that significantly affect daily functioning and quality of life. SCI-110 combines dronabinol, a synthetic form of tetrahydrocannabinol (THC), with palmitoylethanolamide (PEA), an endocannabinoid-like compound believed to enhance therapeutic activity while improving tolerability. According to NeuroThera, this innovative formulation aims to deliver a more effective and safer cannabinoid-based treatment by reducing both tic severity and associated comorbid symptoms without the limitations of currently available therapies. The company believes the therapy has the potential to become a first-of-its-kind treatment approach for adult Tourette Syndrome if future clinical studies confirm its efficacy and safety.
Advertisement
NeuroThera Expands CNS Development Pipeline
The launch of the Yale clinical site represents another milestone in NeuroThera’s expanding development strategy for central nervous system (CNS) disorders. Beyond Tourette Syndrome, the company is advancing SCI-110 for the treatment of Alzheimer’s disease with agitation, while SCI-210 is under development for autism spectrum disorder and status epilepticus. Through its focus on cannabinoid-based pharmaceutical innovation, NeuroThera and parent company SciSparc continue to build a diversified pipeline targeting neurological disorders with significant unmet medical needs. Data generated from the ongoing multinational Phase IIb study are expected to provide critical evidence supporting future regulatory discussions and the continued clinical advancement of SCI-110.
Source:SciSparc press release
